Lead Product(s): Trastuzumab
Therapeutic Area: Oncology
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 15, 2020
ONTRUZANT is being launched in the U.S. by Merck as part of a development and commercialization agreement with Samsung Bioepis.